Seven Eight Capital, LP Repligen Corp Transaction History

Seven Eight Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$194.77 - $324.21 $848,612 - $1.41 Million	-4,357 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$165.87 - $220.95 $722,695 - $962,679	4,357 New	4,357 $870,000
Q1 2020 May 14, 2020	SELL	$84.96 - $109.14 $1.54 Million - $1.97 Million	-18,069 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$73.84 - $93.08 $612,872 - $772,564	8,300 Added 84.96%	18,069 $1.67 Million
Q3 2019 Nov 14, 2019	BUY	$76.65 - $95.51 $748,793 - $933,037	9,769 New	9,769 $749,000
Q1 2019 May 15, 2019	SELL	$49.45 - $62.8 $1.83 Million - $2.32 Million	-36,921 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$48.26 - $68.88 $1.59 Million - $2.27 Million	33,000 Added 841.62%	36,921 $1.95 Million
Q3 2018 Oct 18, 2018	BUY	$46.8 - $58.97 $183,502 - $231,221	3,921 New	3,921 $217,000

486

54.3M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $7.91B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.